Abraxis BioScience, Inc., has announced the launch of doxorubicin HCl injection, USP 2 mg/mL, the generic equivalent of Adriamycin PFS (Bedford Labs/Boehringer Ingelheim). The productis preservative-free and latex-free.
Doxorubicin is used to produce regression acute lymphoblastic and myeloblastic leukemias; Wilms’ tumor; neuroblastoma; sarcomas, breast, ovarian, thyroid, gastric, bronchogenic, and transitional cell bladder carcinomas; Hodgkin’s disease; and malignant lymphoma.
It is also indicated as part of adjuvant therapy in women with auxiliary lymphnode involvement following resection of primary breast cancer.
(Source: Abraxis, August 9, 2007.)